LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Captures 70% of New Senior Obesity Drug Market Following Medicare Coverage
Eli Lilly CEO Dave Ricks announced that 700,000 seniors have started GLP-1 obesity treatments since Medicare began covering the drugs in July 2026. The company...
Eli Lilly breaks ground on $6.5B Texas plant for weight-loss drugs
Eli Lilly and Company officially broke ground on a $6.5 billion manufacturing campus at Generation Park in Houston, Texas. The project represents the largest...
Eli Lilly traded tariff protection for higher overseas prices in secret deals
A Washington Post investigation revealed secret drug-pricing deals between the Trump administration and Eli Lilly. The agreements reportedly offered Eli Lilly...
Eli Lilly Wins FDA Approval for Breast Cancer Combo, Doubling Survival Results
The U.S. Food and Drug Administration (FDA) granted full approval for Eli Lilly’s Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib). This...
Eli Lilly taps QurCan for brain-penetrating drugs, targeting nervous system diseases
Eli Lilly and Company partnered with Canadian biotech QurCan Therapeutics to develop genetic medicines for the central and peripheral nervous systems. The...
Eli Lilly unveils retatrutide data, reporting 20.8% weight loss in diabetes trial
Eli Lilly and Company will present new cardiometabolic data at the European Association for the Study of Diabetes (EASD) 2026 meeting. The presentations...
🟢 Eli Lilly is trading 3.08% up today ahead of Morgan Stanley conference
Eli Lilly is trading 3.08% up now at $1150.03 as investors focus on the Morgan Stanley Global Healthcare Conference scheduled for September 14, 2026. - The...
Eli Lilly’s Foundayo Prescriptions Rise 8%, Narrowing Gap with Novo Nordisk
Eli Lilly’s oral weight-loss drug, Foundayo, saw total prescriptions climb nearly 8%. Total prescriptions for the drug reached approximately 47,500. Novo...
Eli Lilly commits $25B to deals, diversifying beyond obesity drugs
Eli Lilly CEO David Ricks outlined a strategy to secure growth into the 2030s during a CNBC interview. The company committed over $25 billion to more than 12...
Lilly's Zepbound and Taltz Combo Shows Sustained Efficacy in Psoriatic Disease
Eli Lilly announced positive 52-week results from two Phase 3b trials. The trials showed its weight-loss drug Zepbound, combined with arthritis treatment...
Eli Lilly buys Merida for $2.88B, leveraging obesity profits for autoimmune growth
Eli Lilly entered a definitive agreement to acquire Merida Biosciences for up to $2.88 billion. The deal includes an upfront cash payment plus additional...
Lilly's Heart-Shield Label for Mounjaro Closes a Key Gap With Ozempic — But Can a $10 Billion Drug Still Grow Into Its Price?
Shares of Eli Lilly ticked up 0.6% to $1,183.14 Thursday after the FDA approved its blockbuster diabetes drug Mounjaro to reduce the risk of heart attack,...
Eli Lilly's Mounjaro Wins FDA Approval to Lower Heart Risks in Diabetes
The FDA approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes. This...
🔴 Eli Lilly is trading 3.6% down today — move remains unexplained
Eli Lilly is trading 3.6% down now at $1189.33, extending weakness after declines on August 25 and August 24. - Eli Lilly reported a positive August 26 update...
Eli Lilly, Roche Win FDA Clearance for Alzheimer's Test, Widening Patient Access
The FDA cleared the Elecsys pTau217 blood test co-developed by Eli Lilly and Roche. This test identifies amyloid pathology markers in patients aged 55 and...
Eli Lilly launches Foundayo weight-loss pill in UK, first in Europe
Eli Lilly launched its oral weight-loss and type 2 diabetes pill, Foundayo, in the United Kingdom on Monday. The UK is the first European country to offer the...
Eli Lilly wins NHS backing for Onswik, replacing daily insulin shots
The UK’s National Institute for Health and Care Excellence (NICE) recommended Eli Lilly’s once-weekly insulin, Onswik (efsitora alfa), for NHS use. This...
Polen Capital Reduces Eli Lilly Stake, Trimming a Top Position
In a notable portfolio adjustment, Polen Capital Management reduced its significant stake in pharmaceutical giant Eli Lilly & Co. (LLY) by 27.08% during the...
Eli Lilly Enters Next-Generation RNA Vaccine Field with Amplitude Deal
Eli Lilly entered a research collaboration and licensing agreement with Boston-based Amplitude Therapeutics. The partnership aims to develop vaccines for...
Lilly's GLP-1 Bet on Depression Could Open a Massive New Market — But Can Investors Price In a Drug That Won't Exist Until 2028?
Shares of Eli Lilly surged 5.0% to $1,287.23 on August 19, pushing past the previous session's close of $1,225.73, as investors continued to bid up the stock...